Trial intelligence / Profile preview

APG101 + Reirradiation in Recurrent Glioblastoma

NCT01071837Phase 2Completed

Sponsor
Apogenix
Start
Dec 2009
Primary completion
Oct 2014
Modality
Fc-Fusion Proteins
Countries
2
01

Overview

A Phase 2 trial of asunercept in glioblastoma (GBM), sponsored by Apogenix. Started Dec 2009; status: completed.

02

Drugs

asunercept
03

Conditions

glioblastoma (GBM)

Beyond the preview

Go deeper on NCT01071837.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT01071837.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call